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Patients with phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome and germline mutations in PTEN frequently 
develop lipomatosis, for which there is no standard treatment. Rapamycin was shown to reduce the growth of lipoma cells with 
heterozygous PTEN deficiency in vitro, but concomitantly induced an upregulation of AKT phosphorylation. Since it was shown 
that resveratrol stabilizes PTEN, we asked whether co-incubation with resveratrol could suppress the rapamycin-induced AKT 
phosphorylation in PTEN-deficient lipoma cells. 
Resveratrol incubation resulted in decreased lipoma cell viability by inducing G1-phase cell cycle arrest and apoptosis. PTEN 
expression and AKT phosphorylation were not significantly changed, whereas p70S6 kinase (p70S6K) phosphorylation was 
reduced in PTEN-deficient lipoma cells after resveratrol incubation. Rapamycin/resveratrol co-incubation significantly decreased 
viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation 
alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation. Both 
viability and p70S6K phosphorylation of primary PTEN wild-type preadipocytes were less affected compared to PTEN-deficient 
lipoma cells by equimolar concentrations of resveratrol. These results support the concept of combining chemopreventive natural 
compounds with mammalian target of rapamycin (mTOR) inhibitors to increase the efficacy of chemotherapeutic drugs for patients 
suffering from overgrowth syndromes. 
 
ABBREVIATIONS: AMPK 50-, AMP-activated protein kinase; ERK, extracellular-signal-regulated kinases; IGF-I, insulin-like growth factor-I; IRS-1, insulin 
receptor substrate-1; mTORC1, mammalian target of rapamycin complex 1; PHTS, PTEN hamartoma tumor syndrome; PI3K, phosphatidylinositide 3-
kinase; PTEN, phosphatase and tensin homolog; p70S6K, p70S6 kinase; TSC, tuberous sclerosis complex; SIRT1, sirtuin 1; FCS, fetal calf serum; PI, propidium 
Iodide; DMSO, dimethyl sulfoxide; WST, water-soluble tetrazolium salt; EDTA Ethylenediaminetetraacetic acid; RPIA, radioimmunoprecipitation. 
 
Introduction 
Phosphatase and tensin homolog (PTEN) 
counteracts phosphatidylinositide 3-kinase (PI3K) 
and therefore negatively regulates the 
AKT/mammalian target of rapamycin (mTOR) 
pathway (1). A deficiency in PTEN activity, which 
occurs in PTEN hamartoma tumor syndrome (PHTS) 
and various human cancers, affects cell cycle 
progression, apoptosis, cell metabolism, 
transcription, and translation through activation of 
signaling proteins belonging to the PI3K/AKT/mTOR 
pathway (1). Therefore, inhibitors of this pathway, 
especially inhibitors of mTOR, showed therapeutic 
efficacy in preclinical studies (1). Treatment attempts 
using rapamycin, a specific mTOR  complex  1  
(mTORC1)  inhibitor,  have  been 
 
reported for children with a germline PTEN deletion 
or mutation and suffering from PHTS (2–4). Growth 
of lipomatosis, a frequent PHTS-specific 
complication, was slowed down. However, no 
reduction in lipomatous tumor masses was observed 
(2,3). In vitro, rapamycin decreased cell viability in 
PTEN-deficient lipoma cells (LipPD1), but did not 
induce apoptosis (2). In particular, due to mTOR 
blockade, rapamycin upregulated AKT 
phosphorylation through a negative feedback loop 
via insulin receptor substrate (IRS)-1, leading to 
enhanced cell survival and possibly to drug resistance 
(2,5,6). Resveratrol, a chemopreventive polyphenol 
(7–10), was described to increase PTEN levels and 
promote apoptosis through a decrease in AKT 
phosphorylation in breast cancer cells (11,12). It has 
been reported to inhibit cell proliferation and induce 
apoptosis in vitro in different types of human cancer 
(7,8,13–15) and 3T3L1 preadipocytes (16). 
Furthermore, it was shown that resveratrol inhibited 
not only AKT phosphorylation but also the 
phosphorylation of the mTORC1 target p70S6 
kinase (p70S6K). P70S6K activation promotes 
synthesis of proteins involved, for example, in cell 
cycle progression via phosphorylation of the S6 
ribosomal protein (17–19). A combined use of 
rapamycin and resveratrol showed a modest additive 
inhibitory effect on the growth of different breast 
cancer cell lines mainly by suppressing the 
rapamycin-induced phosphorylation of AKT (12). 
Resveratrol in combination with two other 
polyphenols (quercetin and catechin) was also 
described to be effective in reducing AKT activity, 
inhibiting mTOR signaling, and potentiating the 
inhibitory effect of the epidermal growth factor 
receptor inhibitor gefitinib in breast cancer cells 
(20). Another study highlighted the importance of 
combining rapamycin and polyphenols for cancer 
 
 
therapy, based on their studies with isoflavones in 
combination with rapamycin (9). They described 
that the PI3K/AKT pathway was highly upregulated 
due to a deletion of PTEN and that treatment with 
isoflavones decreased AKT activation (9). We 
therefore investigated whether resveratrol could be 
used as a (co-)medication to improve the described 
effects of rapamycin on PTEN-deficient lipoma cells. 
Methods 
Cell culture 
PTEN-deficient lipoma cells LipPD1 (2) were 
maintained in serum-containing medium 
[DMEM/F12 medium supplemented with 10% fetal 
calf serum (FCS), 1% of penicillin/streptomycin, 
biotin (33 mM), and pantothenic acid (17 mM)] 
(Biochrom AG)  at 37oC and 5% CO2. For 
experiments, cells were seeded in serum-containing 
medium overnight and then stimulated with 
resveratrol (1, 10,  25,  50,  100, 200 mM; 
dissolved in DMSO; Sigma Aldrich) or the 
combination of resveratrol and 100 nM rapamycin 
(Biomol GmbH). DMSO (0.1% in  culture  medium) 
was used as solvent control. Primary human 
subcutaneous (#16899 and #16847) and visceral 
(#14324) PTEN wild-type preadipocytes (LONZA) 
were treated like LipPD1 cells as described above. 
 
 
Cell viability, apoptosis, and cell cycle arrest assay 
To measure cell viability, cells were seeded at a density 
of 4000 cells per well. After stimulation with 
resveratrol alone or in combination with rapamycin, 
WST-1 assay (Roche, Mannheim, Germany) was 
used according to manufacturer’s protocol. 
Apoptosis was detected using the FITC AnnexinV 
Apoptosis Detection Kit (BD Biosciences 
Pharmingen). Cells were seeded at a density of 50,000 
per well in 6-well plates. After collection and 
resuspension in 100 ml AnnexinV-FITC-binding 
buffer, cells were incubated with 8 ml AnnexinV-
FITC and 2 ml propidium iodide (PI) for 10 min at 
4oC in the dark. AnnexinV-FITC-positive and 
AnnexinV-FITC and PI double-positive cells were 
considered to be apoptotic. For cell cycle analysis, 
cells were seeded in 6-well plates at a density of 
35,000–40,000 cells per well, fixed in 70% ethanol 
overnight at 4oC and stained with 50 mg/ml PI for 
30 min at 4oC in the dark. 
 
Protein analyses 
LipPD1 cells were seeded at a density of 200,000 cells 
per well, incubated for 48 h and stimulated with 
10 nM recombinant human insulin-like growth 
factor-I (hIGF-I) (Pharmacia Biotech) for 15 min. 
Cells were lysed with modified RIPA buffer (50 mM 
Tris HCl, pH 7.4; 1% NP40; 0.25% sodium 
deoxycholate; 1x Roche complete proteases inhibitor 
cocktail (Roche); 1 mM EDTA; 1 mM sodium 
orthovanadate; and 1 mM sodium fluoride). 
Immunoblots were performed to detect the amount 
of PTEN, phospho-AKT (Thr308), AKT, phospho-
mTOR (Ser2448), mTOR, phospho-p70S6K 
(Thr389), and p70S6K (New England Biolabs). 
GAPDH (EMD Millipore) served as loading control. 
Appropriate secondary antibodies (Dako) were used. 
Protein bands were detected by Classico LuminataTM 
(Millipore) or AmershamTM ECL (GE Healthcare Life 




Data represent mean § SEM of at least three 
independent experiments. Statistical analysis was 
performed using GraphPad Prism 5 software.  All 
statistics were calculated by unpaired student’s t-
test or one-way analysis of variance (ANOVA) 
followed by Bonferroni multiple comparison test as  
posthoc test. Two-way ANOVA with Bonferroni 
post-test was used to analyze the effects of 
resveratrol when comparing LipPD1 cells with 
primary PTEN wild-type preadipocytes. Two-way 
ANOVA with Bonferroni post-test was also used for 
analyzing cell cycle experiments.   Significant   
differences   were   indicated   as 
*p < 0.05 compared to control cells or rapamycin 




Resveratrol enhances the antiproliferative effect of 
rapamycin on PTEN-deficient lipoma cells (LipPD1) 
by inducing G1-phase cell cycle arrest and apoptosis 
Previously we showed that rapamycin incubation 
of LipPD1 cells resulted in a dose-dependent 
decrease in cell viability (2). We asked whether this 
effect could be enhanced by resveratrol. Therefore, 
viability of LipPD1 cells in response to various 
concentrations of resveratrol alone or a 
resveratrol/rapamycin combination was determined 
following 72-h incubation. Both, stimulation with 
resveratrol alone and in combination with 100 nM 
rapamycin resulted in a dose-dependent inhibition of 
cell viability. At low concentrations of resveratrol (10 
mM), the combination with 100 nM rapamycin 
resulted in a significant further decrease of viability of 
¡28.0 § 12.2% compared to 10 mM resveratrol alone. 
Cell viability was also further decreased at 25 mM 
resveratrol/rapamycin combination (¡26.1 § 11.0%) 
compared to 25 mM resveratrol alone.  At high 
resveratrol  concentrations, the addition of rapamycin 
had no significant effect (¡72.0 § 13.4% decrease in 
cell viability at 200 mM resveratrol/ rapamycin 
combination vs. ¡70.2 § 3.7% at 200 mM resveratrol 
alone) (Fig. 1A). 
To further characterize the effect of resveratrol 
on LipPD1 cells and the mechanism underlying 
 
 
the decrease in cell viability, we asked whether or 
not resveratrol co-incubation had an effect on 
induction of apoptosis or on cell cycle 
progression. After stimulation for 24 h with either 
100 nM rapamycin (Supplementary Fig. 2A) or 
25 and 50 mM resveratrol (Supplementary Fig. 
2B) the number of cells in the G1-phase was 
significantly increased. Rapamycin/resveratrol 
co-incubation resulted in a significantly 
increased number of cells in the G1-phase of 
cell cycle compared to untreated cells (10 mM 
resveratrol C 100 nM rapamycin: 16.24 § 6.09%; 50 
mM resveratrol C 100 nM rapamycin: 32.02 § 
4.2%) and rapamycin incubated cells (10 mM 
resveratrol C 100 nM rapamycin: 13.08 § 2.74%; 
50 mM resveratrol C 100 nM rapamycin: 13.78 § 






Figure. 1. Resveratrol enhances the antiproliferative effect of rapamycin on PTEN-deficient lipoma cells (LipPD1) by inducing G1-phase cell cycle arrest 
and apoptosis. LipPD1 cells were incubated with increasing doses of resveratrol or resveratrol in combination with 100 nM rapamycin for 72 h. A: Cell 
viability was measured by WST-1 assay. B: Cells were stained with AnnexinV/PI for apoptosis detection. C, D: Cells were stained with PI for cell cycle 
analysis. For cell viability analysis, data were normalized to untreated cell values (not shown). 0.1% DMSO was used as solvent control. All data represent 
the mean § SEM of at least three independent experiments performed in triplicates (A) or duplicates (B-D). Statistical analysis was done by one-way 
ANOVA for cell viability and apoptosis analysis (*p < 0.05 vs. control cells; xp < 0.05, compared to cells with resveratrol incubation alone). Two-way 
ANOVA was used for cell cycle analysis. Significant differences were determined in comparison to values of rapamycin incubated cells, *p < 0.05. The 






Figure. 2. Resveratrol incubation of PTEN-deficient lipoma cells (LipPD1) reduces p70S6K phosphorylation. A-E: Western blot analysis was 
carried out using lysates of LipPD1 cells that were incubated with different resveratrol concentrations for 48 h and 10 nM IGF-I for 15 min. GAPDH 
served as loading control. DMSO (0.1%) + IGF-I (solvent control) incubated cells did not differ from IGF-I stimulated control cells in densitometric 
analyses. One typical blot out of four independent experiments is shown. Data were normalized to serum free 
+ IGF-I stimulated values and are presented as mean § SEM. Statistical analysis was performed by one-way ANOVA and Student’s t-test (*p < 0.05 vs. 
control cells). resv: resveratrol; con: control. 
 
No additive effect compared to 10 or 50 mM 
resveratrol incubated cells was detected (Fig. 1C, 
D). 
Resveratrol incubation (10, 25, 50, 100, 200 mM) 
for 72 h significantly increased the number of 
apoptotic cells starting from 50 mM (by 27.2 § 
5.3%) (Fig. 1B). The combination with rapamycin 
did not have an additive effect, although a significant 
induction of apoptosis compared to control cells could 
be detected (Fig. 1B). 
 
Reduction of p70S6K phosphorylation after 
resveratrol and combined resveratrol/rapamycin 
incubation 
Previously it was shown that resveratrol increased 
PTEN protein levels, thereby negatively regulating 
AKT and p70S6K activation (11,12). However, in our 
study, PTEN protein expression was not elevated 
(Fig. 2A, B) and AKT phosphorylation did not 
decline significantly (Fig. 2A, C) in LipPD1 cells 
treated with resveratrol. P70S6K phosphorylation 
was decreased by 75.8 § 17.6% after incubation with  
50 mM resveratrol for 48  h (Fig. 2A, D). In 
addition, mTOR activation was significantly 
decreased after resveratrol incubation (¡49.5 § 
9.9%, Fig. 2E). Total AKT and p70S6K expression 
were not affected. We then asked whether 
resveratrol could potentiate the rapamycin-induced 
decrease in p70S6K activation. When examining the 
combination of rapamycin and resveratrol 
stimulation, an additive effect was 
observed and p70S6K phosphorylation was reduced 
by 97.7 § 1.7% (rapamycin alone: 75.6 § 20%) (Fig. 
3A, B). Phosphorylation of the mTOR target 4E-
binding protein (4E-BP)-1 was not influenced (Fig. 
3C). We asked whether combined effects of 
resveratrol and rapamycin could be mediated via 
activation of AMP-activated kinase (AMPK) and 
subsequent Sirtuin 1 (SIRT1) activation (21). No 
significant effect was observed on AMPK 
phosphorylation, SIRT1 protein levels, or global 
lysine acetylation as a measure for activity of NAD-
dependent deacetylases after incubation of LipPD1 
cells with resveratrol and rapamycin compared to 
controls (Fig. 3D). 
 
PTEN wild-type preadipocytes are less affected than 
lipPD1 preadipocytes at equimolar concentrations 
of resveratrol 
To estimate the effects of resveratrol on normal 
preadipocytes, we determined cell viability and 
p70S6K phosphorylation of three lots of primary 
human PTEN wildtype preadipocytes compared to 
LipPD1 cells after 72-h incubation with resveratrol 
and the combined incubation as described above. 
PTEN wild-type preadipocytes showed a dose-
dependent reduction of cell viability. However, we 
observed that PTEN wild-type preadipocytes were 
significantly less viable at a concentration of 200 mM 
resveratrol, whereas LipPD1 cell viability was 







Figure 3. Reduction of p70S6K phosphorylation after resveratrol/rapamycin incubation of PTEN-deficient lipoma cells (LipPD1) is not influenced 
by AMPK/SIRT1 signaling. Western blot analysis was carried out using lysates of A-D: LipPD1 cells that were incubated with a 50 mM resveratrol/100 
nM rapamycin combination for 48 h and 10 nM IGF-I for 15 min. GAPDH served as loading control. DMSO (0.1%) 
+ IGF-I (solvent control) incubated cells did not differ from IGF-I stimulated control cells in densitometric analyses. One representative blot is shown. 
B: Data were normalized to serum free + IGF-I stimulated values and are presented as mean § SEM. Statistical analysis was performed by one-way 
ANOVA and Student’s t-test (*p < 0.05 vs. control cells). resv: resveratrol; rapa: rapamycin. 
 
(Fig. 4A). The co-stimulation also led to a dose-
dependent inhibition in LipPD1 cells and PTEN 
wild-type human preadipocytes. In contrast to the 
results obtained with resveratrol alone, cell viability 
of both cell cultures was  significantly  decreased  by  
100  nM  rapamycin/ 200 mM resveratrol 
combination (Fig. 4B). Since we observed a 
significantly different response in cell viability at 50 
mM resveratrol, we determined p70S6K activation of 
LipPD1 cells and PTEN wild-type preadipocytes after 
stimulation with 50 mM resveratrol. LipPD1 cells 
showed a stronger decrease of p70S6K 
phosphorylation than PTEN wild-type preadipocytes. 
Total p70S6K protein was not affected by resveratrol 
incubation (Fig. 4C). 
 
Discussion 
Rapamycin as inhibitor of mTORC1 (22) has been 
clinically used to treat cancers associated with 
increased activity of the PI3K/AKT/mTOR pathway 
(23,24). Individual treatment attempts applying 
rapamycin have been described for patients with 
germline deletions or mutations of PTEN and PHTS 
(2–4). However, resistance to rapamycin was 
observed in treated cell lines, mouse models, and 
human tumor samples (2,9,12,25–27). This effect was 
found to be frequently due to p70S6K-mediated 
downregulation  of IRS-1 serine  phosphorylation 
and concomitant AKT activation (2,6,28). P70S6K is 
a target of mTORC1 and regulates protein synthesis 
(29). It also mediates mTOR signaling in the negative 
feedback regulation of the PI3K/AKT/mTOR 
pathway by phosphorylation of IRS-1 that is upstream 
of PI3K (28,30–32). Recent studies focused on a 
combined use of rapamycin with other agents to 
overcome the hyperactivation of AKT. The combined 
treatment of breast cancer or glioblastoma cell lines 
with rapamycin and chemopreventive agents such as 
isoflavones or resveratrol was shown to decrease cell 
viability and activation of AKT (9,12). Based on these 
studies and the reported capability of resveratrol to 
elevate PTEN levels (11,12), we sought to evaluate the 
combined therapy of rapamycin and resveratrol on 
activation of AKT and the mTORC1 target p70S6K 
and cell survival of PTEN-deficient lipoma cells 
(LipPD1) in vitro. In contrast to the studies mentioned 







Figure. 4. Viability and p70S6K phosphorylation of PTEN wild-type preadipocytes (PP) are less affected by resveratrol incubation than PTEN-
deficient lipoma cells (LipPD1). LipPD1 cells and primary human PTEN wild-type preadipocytes were incubated with A: increasing doses of 
resveratrol alone or B: in combination with 100 nM rapamycin for 72 h. WST-1 assay was performed to assess cell viability. Data are presented as mean 
x SEM of three independent experiments. Cells treated with 0.1% DMSO were set to 1 and served as control cells. 
Statistical analysis was performed by two-way ANOVA and Bonferroni post-test (_p < 0.05 vs. control cells). C: LipPD1 cells and primary human 
PTEN wild-type PP (two different lots) were incubated with 50 mM resveratrol for 48 h to analyze p70S6K phosphorylation levels. 
GAPDH served as loading control. Densitometric analysis data are shown above the bands. One typical blot out of two independent experiments is 
shown. PP: primary human PTEN wild-type preadipocytes; resv: resveratrol; rapa: rapamycin. 
 
 
(11,12) and significant decrease of AKT 
phosphorylation (12,15,33,34) after treatment of 
LipPD1 cells with resveratrol, although similar 
resveratrol concentrations were used. However, other 
studies also described an activation of AKT after 
resveratrol treatment (34,35). Emphasizing that 
resveratrol did not significantly decrease the 
activation of AKT in LipPD1 cells, we focused on 
p70S6K activity as being most affected after 
incubation with resveratrol alone. Compared to 
incubation with rapamycin alone, a combined therapy 
potentiated the reduction of p70S6K activity and 
subsequently reduced phosphorylation of the S6K 
target ribosomal protein S6. Interestingly, 4E-BP-1 as 
another target of mTORC1 besides p70S6K was not 
significantly affected by resveratrol. This would point 
to a direct inhibition of p70S6K (18,19). Resveratrol 
was more effective on LipPD1 cells, since primary 
human PTEN wild-type preadipocytes were less 
affected at equimolar concentrations. 
The described decrease in cell viability caused 
by resveratrol incubation alone could be explained 
by either induction of cell cycle arrest or apoptosis 
depending on the resveratrol concentration. Lower 
concentrations, especially 10 and 50 mM, resulted 
in a significant increase of G1-phase cell  cycle  arrest 
after 24 h, whereas a longer incubation period (72 
h) with higher resveratrol concentrations  (50, 100,  
and 200 mM) led to apoptosis induction. We found 
that 50 mM resveratrol affected cell cycle arrest after 
24 h, but significantly induced apoptosis after 72 
h. Interestingly, the significant difference in the 
reduction of LipPD1 cell viability after incubation 
with the rapamycin/resveratrol co-incubation could  
be  explained by an additive effect of resveratrol on 
cell cycle arrest, but not on apoptosis. The 
diminishing difference in cell viability between 
resveratrol incubation alone and 
rapamycin/resveratrol co-incubation might be due to 
the cytotoxic effects of resveratrol at higher 
concentrations (36,37). mTOR activity is regulated by 
the upstream complex tuberous sclerosis complex 
(TSC)1/TSC-2, which inhibits the mTOR activator 
RHEB and is inhibited through phosphorylation by 
AKT (38,39). Other signaling molecules that act 
upon TSC1/TSC2 to regulate mTOR activity are 
SIRT1 (7,40,41) and WNT (42). AMPK (43–45) and 
PRAK can suppress mTORC1 by acting upon 
mTORC1 itself  and  TSC2  or  its  upstream  activator  
RHEB, respectively. Resveratrol as an activator of the 
AMPK/ SIRT1 axis had no influence on AMPK 
phosphorylation or SIRT1 protein levels in LipPD1 
cells. In line with these results, global lysine 
acetylation as a measure for the activity of NAD-
dependent deacetylases, like sirtuins, was not affected 
by resveratrol treatment. Overall, our results 
emphasize the importance of chemopreventive natural 
compounds, such as resveratrol, as potentiating agents 
in combination with mTOR inhibitors (47) to increase 
the efficacy of drugs applied as treatment option for 
patients with PHTS-associated lipomatosis. 
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